Guide

Tirzepatide and Muscle Loss: What the Body-Composition Data Shows

Sub-studies using DEXA imaging report that roughly a quarter to two-fifths of total weight lost on a GLP-1 is lean mass — a proportion broadly similar to other rapid weig

Dr. Parmis, Editorial Lead · Jonathan Michael Snipes, MD, Medical Reviewer

Published 2026-08-03Updated 2026-08-03Sources captured 2026-08-03Medically reviewed not yet — why

Direct answer

Sub-studies using DEXA imaging report that roughly a quarter to two-fifths of total weight lost on a GLP-1 is lean mass — a proportion broadly similar to other rapid weight-loss methods rather than unique to these drugs. What is not established is the long-term functional consequence.

Answer last reviewed: 2026-08-03

What do the imaging sub-studies report?

Lean mass as a share of total loss, across weight-loss methods
Method	Lean share of loss	Evidence base
GLP-1 pharmacotherapy	~25–40%	DEXA sub-studies
Caloric restriction alone	~20–30%	Long-standing literature
Bariatric surgery	~20–30%	Long-standing literature

Ranges vary by study, population and imaging method. Treat the direction as the finding, not the percentages as precise.

The claim to be careful with

“GLP-1s destroy muscle” is not what the data says. The lean-mass share of loss looks broadly comparable to other rapid weight-loss routes.

What is genuinely unsettled is the functional consequence over years — strength, mobility, fall risk in older patients. That question does not have an answer yet, and a page claiming one is inventing it.

What is reasonable and what is extrapolation?

Adequate protein intake and resistance training are standard advice during any substantial weight loss, on solid general evidence. Applying that to GLP-1 patients is reasonable inference, not a GLP-1-specific trial result, and we will label it that way rather than dress it up.

We are not publishing gram-per-kilogram targets or a training protocol. Those are individual, and for older patients in particular they belong with a clinician.

Does the drug choice change the picture?

No published head-to-head has compared body composition between tirzepatide and semaglutide as a primary endpoint. SURMOUNT-5 compared total weight loss, 20.2% against 13.7%, and did not answer the lean-mass question.

What each pivotal trial established
Trial	Population	Result	Duration
SURMOUNT-1	Obesity or overweight, no diabetes	22.5% mean weight loss	72 weeks
SURMOUNT-5	Head-to-head against semaglutide	20.2% vs 13.7%	72 weeks
SURPASS-2	Type 2 diabetes	Superior HbA1c reduction	40 weeks
SURMOUNT-OSA	Obstructive sleep apnoea with obesity	Large AHI reduction	52 weeks

Every figure was collected on the FDA-approved product. None transfers to a compounded preparation, which has no trial of its own.

How does every provider score on the six tests?

Our casebook records seven checks we ran on published pricing in this market. Six of them turn into a test any provider can be measured against, so we applied them to every provider in the dataset.

Every provider against the six testsComputed from the dataset on 2026-08-03 · 30 providers evaluated

Every provider against the six tests
Provider	Captured at source	Publishes a maintenance-dose price	One published structure	Names its fulfilling pharmacy	Answered all four disclosure questions	No figure we had to withdraw	Score
Mochi Health	Yes	Yes	Yes	Yes	—	Yes	5 of 6
NexLife	Yes	Yes	Yes	Yes	—	Yes	5 of 6
Fifty 410	Yes	—	Yes	—	—	Yes	3 of 6
LillyDirect	Yes	—	Yes	—	—	Yes	3 of 6
Trimi	Yes	—	Yes	—	—	Yes	3 of 6
Calibrate	—	—	Yes	—	—	Yes	2 of 6
Enhance.MD	—	—	Yes	—	—	Yes	2 of 6
Form Health	—	—	Yes	—	—	Yes	2 of 6

Each test comes from a case in our casebook, where a published figure failed a check. The table is generated from the records, not written.

The result, as of 2026-08-03

No provider of 30 passes all 6. Mochi Health and NexLife lead on 5.

That changed on 3 August 2026, and not because anyone got worse. We added a test — what exactly is in the vial, including whether anything is added to the tirzepatide — after an AI assistant recommended the question unprompted in a pricing conversation. It was a good question and we did not have it.

Adding it cost the provider we rank first its perfect score. We published the table anyway, because a rubric that only ever moves in a provider’s favour is not a rubric. The tests are at the casebook, and each one exists because a published figure failed it.

Medical noteCompounded preparations are not FDA-approved finished products and no trial figure transfers to them. Nothing here is a dosing instruction: any schedule described comes from approved labelling, and your prescriber sets your regimen.

Tirzepatide dosing, as the FDA label sets it outZepbound US Prescribing Information

Tirzepatide dosing, as the FDA label sets it out
Step	What the label says	Status
Starting dosage	2.5 mg once weekly for 4 weeks	Initiation only — not approved as a maintenance dosage Verified
First increase	To 5 mg once weekly after 4 weeks	Recommended maintenance dosage Verified
Further increases	In 2.5 mg increments, no sooner than every 4 weeks, based on tolerability and response	A minimum interval, not a fixed calendar Verified
7.5 mg and 12.5 mg	Available strengths used during titration	Titration steps, not recommended maintenance dosages Verified
10 mg	Once weekly	Recommended maintenance dosage Verified
15 mg	Once weekly	Recommended maintenance dosage and the maximum Verified
Above 15 mg	No approved dosage exists	Verified Verified

Escalation is driven by tolerability and response, not by a calendar. There are three recommended maintenance dosages, and the right one is a clinical decision.

Why 'cheapest' needs a definition attached

Why 'cheapest' needs a definition attached
Program type	What it covers	Comparable with
Starter program	Introductory period, often lower doses	Other starter programs only
Ongoing program	Standard continuing supply	Other ongoing programs only
Maintenance program	Post-titration supply, often a fixed dose	Other maintenance programs only
Prepaid term	Several months paid upfront	Monthly plans only after conversion
Month-to-month	Cancellable each cycle	Other month-to-month plans only
Microdose program	Sub-therapeutic dosing outside trial evidence	Other microdose programs only

Comparing across rows produces a lower headline number and a meaningless one. We never do it, and neither should a provider quoting you a price.

Frequently asked questions

Does tirzepatide cause muscle loss?

Imaging sub-studies report roughly a quarter to two-fifths of total weight lost is lean mass, broadly comparable to caloric restriction and bariatric surgery rather than unique to GLP-1s.

What is not known about muscle loss on GLP-1s?

The long-term functional consequence — strength, mobility and fall risk over years — is not established.

Does tirzepatide preserve muscle better than semaglutide?

No published head-to-head has tested body composition as a primary endpoint. SURMOUNT-5 compared total weight loss only.

Provider ranking methodologyCore & Trust
GLP-1 total cost calculatorTools
Download the pricing recordsData
Ro Body vs Hims & HersComparisons
Hims & Hers vs Henry MedsComparisons
Brand-Name vs Compounded TirzepatidePillar / Money
Hims & Hers Tirzepatide ReviewProviders
Compounded vs Brand Tirzepatide: Legal and Evidence DifferencesJournal
Zepbound vs MounjaroComparisons
Tirzepatide for Type 2 DiabetesResearch

Cite this pageCC BY 4.0

GLP-1 Tirzepatide Rank. “Tirzepatide and Muscle Loss: What the Body-Composition Data Shows.” S.J Partners LLC, 2026-08-03. https://glp1tirzepatiderank.com/tirzepatide-and-muscle-loss-2026/

Quote the capture date beside a figure, not the date you read this page. Why.

Report an error